Advancing Cancer-care through CANScript Enabled Personalized Treatment (ACCEPT): A non randomized, investigator initiated, observational trial to measure predictive power of CANScriptTM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer - ACCEPT

Mitra Biotech Pvt Ltd0 个研究点目标入组 195 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients with Ca-H&N requiring neo-adjuvant therapy or refractory/ relapsed triple negative breast cancer , aged 18-75 are eligible for the ACCEPT trial.
•2. Patients from whom at least 100-200 mm3 non-necrotic tumor can be obtained by biopsy or surgery.
•3.ECOG Performance Status of 0 - 1
•4. Triple NEgative BReast cancer patients must be tested negative for ER, PR & HER2 receptor expression

•Any other concurrent disease or illness, which in the judgment of the investigator would make the subject inappropriate for entry into the study.

发起方